{"title":"通过金合欢胶干预减轻fca诱导的关节炎大鼠模型的炎症和氧化应激:一项全面的体内研究","authors":"Sobia Khalid Awan, Ali Sharif, Bushra Akhtar","doi":"10.1007/s10787-025-01907-7","DOIUrl":null,"url":null,"abstract":"<p><p>Rheumatoid arthritis is a persistent immune-mediated inflammatory disorder that primarily affects joint bones, impacting approximately 0.5-1.0% of the global population. People with RA are 1.5 times more likely to develop cardiovascular conditions, including atherosclerosis. This study explored the therapeutic potential of GAc in a rat model of RA induced by CFA, focusing on its impact on biomarkers associated with atherosclerosis. Molecular docking studies indicated strong binding affinities of GAc with key inflammatory cytokines, including TNF-α, IL-6, IL-1β, NF-κB and PRMT-1. The experimental model of 23 days involved the induction of arthritis by injecting 0.15 mL of CFA into the sub-plantar region of the rats' left hind paws. GAc was dissolved in distilled water and administered to rats via oral gavage. Our results revealed that the administration of GAc, particularly in combination with MtxSt (GAc 10 g/kg + MtxSt), significantly (p < 0.001) reduced arthritic scores, joint stiffness scores, paw thickness, levels of lipids (LDL, VLDL, TG, and TC), asymmetric dimethylarginine (ADMA), homocysteine, oxidative stress, and pro-inflammatory cytokines. In addition, GAc markedly (p < 0.001) improved body weight, hematological parameters (RBC, %HCT and Hb), HDL, dimethylarginine dimethylaminohydrolase-1(DDAH-1), and CST levels. Histopathological assessments showed that GAc 10 g/kg + MtxSt significantly alleviated bone and cartilage erosion (p < 0.001), pannus formation (p < 0.001), synovial hyperplasia (p < 0.01), vascular congestion (p < 0.001) and inflammatory cell infiltration (p < 0.001). The therapeutic efficacy of GAc is ascribed to its anti-inflammatory, antioxidant, and anti-atherosclerotic properties. This study suggested that combining GAc with MtxSt exerts a synergistic effect in mitigating inflammation and reducing the risk of atherosclerosis associated with RA.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"5365-5385"},"PeriodicalIF":5.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mitigation of inflammation and oxidative stress in FCA-induced arthritic rat model through gum acacia intervention: a comprehensive in‑vivo study.\",\"authors\":\"Sobia Khalid Awan, Ali Sharif, Bushra Akhtar\",\"doi\":\"10.1007/s10787-025-01907-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rheumatoid arthritis is a persistent immune-mediated inflammatory disorder that primarily affects joint bones, impacting approximately 0.5-1.0% of the global population. People with RA are 1.5 times more likely to develop cardiovascular conditions, including atherosclerosis. This study explored the therapeutic potential of GAc in a rat model of RA induced by CFA, focusing on its impact on biomarkers associated with atherosclerosis. Molecular docking studies indicated strong binding affinities of GAc with key inflammatory cytokines, including TNF-α, IL-6, IL-1β, NF-κB and PRMT-1. The experimental model of 23 days involved the induction of arthritis by injecting 0.15 mL of CFA into the sub-plantar region of the rats' left hind paws. GAc was dissolved in distilled water and administered to rats via oral gavage. Our results revealed that the administration of GAc, particularly in combination with MtxSt (GAc 10 g/kg + MtxSt), significantly (p < 0.001) reduced arthritic scores, joint stiffness scores, paw thickness, levels of lipids (LDL, VLDL, TG, and TC), asymmetric dimethylarginine (ADMA), homocysteine, oxidative stress, and pro-inflammatory cytokines. In addition, GAc markedly (p < 0.001) improved body weight, hematological parameters (RBC, %HCT and Hb), HDL, dimethylarginine dimethylaminohydrolase-1(DDAH-1), and CST levels. Histopathological assessments showed that GAc 10 g/kg + MtxSt significantly alleviated bone and cartilage erosion (p < 0.001), pannus formation (p < 0.001), synovial hyperplasia (p < 0.01), vascular congestion (p < 0.001) and inflammatory cell infiltration (p < 0.001). The therapeutic efficacy of GAc is ascribed to its anti-inflammatory, antioxidant, and anti-atherosclerotic properties. This study suggested that combining GAc with MtxSt exerts a synergistic effect in mitigating inflammation and reducing the risk of atherosclerosis associated with RA.</p>\",\"PeriodicalId\":13551,\"journal\":{\"name\":\"Inflammopharmacology\",\"volume\":\" \",\"pages\":\"5365-5385\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Inflammopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10787-025-01907-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01907-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
类风湿关节炎是一种持续的免疫介导的炎症性疾病,主要影响关节骨骼,影响全球约0.5-1.0%的人口。类风湿性关节炎患者患心血管疾病(包括动脉粥样硬化)的可能性是常人的1.5倍。本研究探讨了GAc在CFA诱导的RA大鼠模型中的治疗潜力,重点关注其对动脉粥样硬化相关生物标志物的影响。分子对接研究表明,GAc与TNF-α、IL-6、IL-1β、NF-κB、PRMT-1等关键炎症细胞因子具有较强的结合亲和力。第23天的实验模型是在大鼠左后爪足底下区注射0.15 mL CFA诱导关节炎。将GAc溶解于蒸馏水中,灌胃给鼠。我们的研究结果显示,GAc的施用,特别是与MtxSt (GAc 10 g/kg + MtxSt)联合使用,显著(p
Mitigation of inflammation and oxidative stress in FCA-induced arthritic rat model through gum acacia intervention: a comprehensive in‑vivo study.
Rheumatoid arthritis is a persistent immune-mediated inflammatory disorder that primarily affects joint bones, impacting approximately 0.5-1.0% of the global population. People with RA are 1.5 times more likely to develop cardiovascular conditions, including atherosclerosis. This study explored the therapeutic potential of GAc in a rat model of RA induced by CFA, focusing on its impact on biomarkers associated with atherosclerosis. Molecular docking studies indicated strong binding affinities of GAc with key inflammatory cytokines, including TNF-α, IL-6, IL-1β, NF-κB and PRMT-1. The experimental model of 23 days involved the induction of arthritis by injecting 0.15 mL of CFA into the sub-plantar region of the rats' left hind paws. GAc was dissolved in distilled water and administered to rats via oral gavage. Our results revealed that the administration of GAc, particularly in combination with MtxSt (GAc 10 g/kg + MtxSt), significantly (p < 0.001) reduced arthritic scores, joint stiffness scores, paw thickness, levels of lipids (LDL, VLDL, TG, and TC), asymmetric dimethylarginine (ADMA), homocysteine, oxidative stress, and pro-inflammatory cytokines. In addition, GAc markedly (p < 0.001) improved body weight, hematological parameters (RBC, %HCT and Hb), HDL, dimethylarginine dimethylaminohydrolase-1(DDAH-1), and CST levels. Histopathological assessments showed that GAc 10 g/kg + MtxSt significantly alleviated bone and cartilage erosion (p < 0.001), pannus formation (p < 0.001), synovial hyperplasia (p < 0.01), vascular congestion (p < 0.001) and inflammatory cell infiltration (p < 0.001). The therapeutic efficacy of GAc is ascribed to its anti-inflammatory, antioxidant, and anti-atherosclerotic properties. This study suggested that combining GAc with MtxSt exerts a synergistic effect in mitigating inflammation and reducing the risk of atherosclerosis associated with RA.
期刊介绍:
Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas:
-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states
-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs
-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents
-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain
-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs
-Muscle-immune interactions during inflammation [...]